
Disc Medicine Investors Face Investigation Over Misleading Disclosure Claims
A 22% plunge in stock price followed a February 13, 2026, FDA rejection of Disc Medicine’s bitopertin program, prompting the Rosen Law Firm to launch an investigation into potential securities fraud. The firm alleges the company may have misled the public regarding its regulatory filings and business prospects.




















